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Abstract Arthritis is among the leading causes of dis-
ability in the developed world. There remains no cure for
this disease and the current treatments are only modestly
effective at slowing the disease’s progression and provid-
ing symptomatic relief. The clinical effectiveness of
current treatment regimens has been limited by short half-
lives of the drugs and the requirement for repeated sys-
temic administration. Utilizing gene transfer approaches
for the treatment of arthritis may overcome some of the
obstacles associated with current treatment strategies. The
present review examines recent developments in gene
therapy for arthritis. Delivery strategies, gene transfer
vectors, candidate genes, and safety are also discussed.
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Introduction
Rheumatoid arthritis (RA) is the most common inﬂamma-
tory disorder, affecting approximately 0.5–1% of the North
American adult population. It causes signiﬁcant pathology
and functional impairment in affected individuals. RA is a
multifactorial disease whose main risk factors include
genetic susceptibility, sex and age, smoking, infectious
agents, hormones, diet, and socioeconomic and ethnic
factors [1]. Those afﬂicted by RA report a decrease in
quality of life measures such as persistent pain, functional
disability, fatigue, depression, and an inability to perform
daily tasks [2]. RA is also a signiﬁcant burden on the health
care system, averaging between $2,800–$28,500 per patient
per year for direct and indirect costs in developed countries
[3]. Although the pathogenesis of RA is not completely
understood, speciﬁc HLA-DR genes, autoantibody and
immune complex production, T cell antigen-speciﬁc
responses, networks of cytokine production, and a hyper-
plastic synovium have all been shown to play a role.
RA primarily affects diarthrodial joints of the hands and
feet. These joints are normally lined by a thin cell layer
(1–3 cells) of both type I (macrophage-like) and type II
(ﬁbroblast-like) synoviocytes. In RA, the joint is inﬂamed
and the synovium becomes hyperplastic, creating a pannus
of synovial tissue comprised of CD4+ T cells, B cells, mast
cells, dendritic cells, macrophages, and synoviocytes that
invade and destroy nearby cartilage and bone. Neutrophils
accumulate in the synovial ﬂuid and also contribute to the
destructive processes [4, 5]. Macrophages and ﬁbroblast-
like synoviocytes (FLS) secrete inﬂammatory cytokines,
such as TNFa, IL-1b, and IL-6, all of which contribute to
cartilage and bone destruction. They have been implicated
as major contributors to many aspects of RA, including
inﬂammatory cell inﬁltration, ﬁbrosis, and T cell prolifer-
ative responses [6, 7]. These cytokines are thought to act
primarily through MAP kinase and nuclear factor jB
(NFjB) signaling pathways to activate transcription factors
that turn on genes for chemokines and cell adhesion mol-
ecules, along with extracellular matrix degrading enzymes
like matrix metalloproteinases (MMPs). Chemokines and
chemokine receptors have also been linked to RA [6, 8, 9].
Initial treatment strategies for RA include drugs such
as non-steroidal anti-inﬂammatory drugs (NSAIDs) and
glucocorticoids. While providing pain relief and decreased
joint swelling, these drugs are unable to stop the progression
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DOI 10.1007/s10165-007-0017-9of RA [10]. This led to the use of small molecules like
methotrexate that were demonstrated to slow disease pro-
gression. For many decades these disease-modifying agents
of rheumatic disease (DMARDs) were the best treatment
option for RA. In recent years, a further understanding of
the disease process has led to the development of biologic
DMARDs primarily aimed at neutralizing the effects of pro-
inﬂammatory cytokines. The most successful agents in this
class are anti-TNF-a molecules and IL-1b blocking agents.
Based on improvement criteria set forth by the American
College of Rheumatology (ACR), these drugs are more
effective than treatment with methotrexate alone. Even so,
less than half of the patients show improvement of at least
50% in their ACR scores. In addition, the half-life of these
drugs is relatively short and they require frequent systemic
administration in order to be effective [11]. Gene transfer
strategies have the potential to overcome some of these
limitations, potentially leading to increased efﬁcacy and
decreased frequency of administration.
Gene delivery strategies
Although the majority of inﬂammation in RA is localized
to the joints, there are systemic components to the disease.
Therefore, when developing treatment strategies, one must
consider whether the therapy should be delivered locally or
systemically. Local administration is attractive because it
has less potential for side effects and the treatment is
delivered directly to the joint, the main site of inﬂamma-
tion. However, systemic features of the disease would seem
to be left untreated. Interestingly, several researchers have
observed a ‘‘contralateral effect’’ in animal models of local
gene delivery where the delivered transgene is protective
not only to the injected joint, but also to distal, untreated
joints [12–14]. This effect appears to be independent of
trafﬁcking of modiﬁed immune cells to distal joints,
because ex vivo modiﬁed ﬁbroblasts alone are still able to
confer a contralateral effect [15]. It is also independent of
systemic circulating levels of transgene and non-speciﬁc
immunosuppression and instead was found to depend on a
complex antigen-speciﬁc mechanism [16]. Systemic
delivery, typically by intravenous administration, would be
expected to have a broader therapeutic effect, but is also
associated with an increase in side effects and toxicity.
Another consideration for gene transfer is whether to
employ in vivo or ex vivo delivery strategies. In vivo
strategies have the advantage of being relatively easy and
less expensive. In addition, many more studies have been
performed in animal models looking at in vivo gene
delivery. Ex vivo strategies, although expensive and time-
consuming, have the advantage of being able to treat and
select very speciﬁc cells, avoiding the possibility that the
gene transfer vector could genetically modify a stem cell
population and result in oncogene activation. A phase I
clinical trial has been performed using a retroviral vector to
deliver IL-1 receptor antagonist (IL-1ra) to cultured
autologous synovial ﬁbroblasts [17]. The cells were then
injected into the RA patients’ joints. After a scheduled
arthroplasty 1 week later, signiﬁcant expression of the
transgene was seen in the injected joints. No adverse events
were reported. This trial was initiated following previous
experiments where antagonists of both IL-1b and TNF-a
were delivered to autologous cultured rabbit ﬁbroblasts ex
vivo and injected into arthritic rabbit knee joints, with
signiﬁcant therapeutic beneﬁt [15, 18].
Most ex vivo studies use ﬁbroblast-like synoviocytes
(FLS) as the target cell. These cells have been targeted
speciﬁcally because they are thought to be directly
responsible for cartilage destruction and drive and perpet-
uate the inﬂammatory response and autoimmunity [19].
The disadvantages of using this cell type are that FLS have
a low proliferation rate, lack highly speciﬁc surface
markers, and are a non-homogenous population. Future
studies may examine other strategies, including gene
delivery to T cells, dendritic cells, muscle cells, or mes-
enchymal stem cells [20].
Gene transfer vectors
Gene transfer vectors can be broadly categorized into two
groups: viral and non-viral vectors. In general, viral vectors
tend to provide for longer-term gene expression but often
come with additional safety concerns, ranging from fears of
generating replication competent virus during vector pro-
duction, random insertion of the transgene into the genome
following treatment, or development of a harmful immune
response.
Plasmid DNA
The most common non-viral vector used in arthritis studies
is plasmid DNA. Plasmid DNA can be delivered by lipo-
somes, gene gun, or direct injection of the plasmid. The use
of plasmid DNA tends to be less toxic and less immuno-
genic than the use of viral vectors and is also easy and
relatively inexpensive to produce. However, plasmid DNA
often leads to low transfection efﬁciency and short-term
expression of the transgene, lasting only 1–2 weeks
[21–23]. These limitations make it unlikely that local
delivery of plasmid DNA in the joint will be successful.
The most success with the use of plasmid DNA in gene
transfer for arthritis has been garnered through delivery of
transgenes to skeletal muscle. Electrotransfer of soluble
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onset of collagen-induced arthritis (CIA) led to a decrease
in the clinical and histological signs of disease for up to
5 weeks [24]. Similarly, plasmids encoding cDNA for
other anti-inﬂammatory molecules such as IL-1ra and a
soluble TNFR-Fc fusion protein have been demonstrated to
improve both macroscopic and microscopic scores of CIA
when delivered intramuscularly [25, 26]. Plasmid encoding
TGF-b delivered to skeletal muscle delayed progression of
streptococcal cell wall induced arthritis when administered
at the peak of the acute phase and virtually eliminated
subsequent inﬂammation and arthritis when given at the
beginning of the chronic phase of the disease [27]. Intra-
muscular injections of plasmids encoding immuno-
modulatory molecules such as IL-4, IL-10, viral IL-10, and
soluble complement receptor type I have given similar
results [28–31]. Intramuscular delivery of a plasmid
encoding TIMP-4, and inhibitor of matrix metalloprotein-
ases, completely abolished the development of arthritis in a
rat adjuvant-induced arthritis model [32]. Intravenous
delivery of a plasmid encoding the heparin-binding domain
of ﬁbronectin inhibited leukocyte recruitment and
decreased inﬂammation in CIA [33]. Intra-dermal injection
of plasmid encoding IL-10 and intra-peritoneal injection of
plasmid IL-10/liposome complexes have also been dem-
onstrated to delay onset and progression of CIA [34, 35].
The liposome delivered DNA was able to maintain
expression for only 10 days after injection, signiﬁcantly
less than the intramuscular studies mentioned above.
Recently, the use of chitosan, a polycationic polysaccha-
ride derived from crustacean shells, has been shown to act
as an efﬁcient gene carrier to rabbit knee joints both in
vitro and in vivo [36].
Other non-viral vectors
Other non-viral gene delivery systems that have potential in
the treatment of RA are the artiﬁcial chromosome expres-
sion (ACE) system and the sleeping beauty (SB) transposon
system. The ACE system is attractive because it is non-
integrating and can provide stable and long-term gene
expression of one or multiple genes. A feasibility study was
recently performed in a Mycobacterium tuberculosis rat
arthritis model, which demonstrated that rat skin ﬁbroblasts
could be modiﬁed ex vivo to express a reporter gene from
an artiﬁcial chromosome. These cells, when subsequently
injected into rat joints, demonstrated engraftment into the
synovial tissue microarchitecture and detectable transgene
expression. The ACE system did not induce local inﬂam-
mation at the injection site that is often associated with viral
vector administration [37]. The sleeping beauty transposon
system melds the advantages of both viral and non-viral
vectors, allowing for both integration into the genome and
long term expression. No studies have yet been performed
in arthritis models using the sleeping beauty transposon
system, but success has been found in both cancer and
hemophilia models, suggesting that it might be have
potential to successfully treat arthritis as well [38].
Viral vectors are by far the most widely used vectors for
delivering transgenes in arthritic animal models [39]. There
are several different viral vectors that have been examined
for use in gene transfer for arthritis, including adenovirus,
retrovirus, adeno-associated virus (AAV), and lentivirus,
each with their respective advantages and disadvantages.
Adenovirus
Adenovirus is a non-encapsidated double-stranded DNA
virus that can infect non-dividing cells and can be produced
at high titers. Many gene-therapy studies have been per-
formed with this vector but it has several limitations
that may prevent it from being successful in the clinic. The
high prevalence of neutralizing antibodies may prevent
successful administration or re-administration. Injected
adenovirus also causes a signiﬁcant inﬂammatory immune
response, which is a safety concern. In addition, adenovirus
vectors typically only allow for 1–3 weeks of transgene
expression, which would limit its long-term efﬁcacy. Some
improvements to adenoviral vectors have recently been
made in an effort to improve delivery of transgenes to the
synovium. FLS lack the coxsackie-adenovirus receptor
(CAR) and are not efﬁciently transduced by adenovirus. By
modifying the ﬁber knobs on the virus, adenoviral transgene
delivery to synoviocytes and synovium was improved dra-
matically [40, 41]. Other recent improvements include the
development of an adenoviral vector with an inﬂammation
inducible promoter [42]. This would allow expression of the
transgene during active disease, but expression would turn
off once inﬂammation was brought under control.
Retrovirus
Retroviruses, mostly derived from the Moloney murine
leukemia virus, have a relatively simple genome and
structure. They are enveloped viruses and contain two
identical copies of their RNA genome. The key feature of
the retroviral life cycle is the ability of the RNA genome to
be reverse transcribed into double-stranded DNA, which
can then randomly integrate into the genome. They have
been mostly used in ex vivo studies and are desirable
vectors for several reasons. They can provide for long-term
stable expression and their integration into the genome
makes it possible to permanently correct a genetic defect
4 Mod Rheumatol (2008) 18:2–14
123[43]. For arthritis in particular, the inﬂamed synovium
appears to be more susceptible to uptake of the virus [18].
The drawbacks to retroviral vectors are that they only
infect non-dividing cells and are produced at low titers.
The fact that these vectors integrate into the genome ran-
domly is also a concern. In fact, in a recent clinical trial in
France using a retrovirus to correct an X-linked SCID
disorder, 3 out of 10 children developed leukemia after the
vector inserted in or near a known oncogene. As a result,
similar trials in the U.S. for this disorder have been halted
until more information can be gathered [44, 45]. Future
improvements to these vectors, including the development
of self-inactivating vectors, which contain no retroviral
promoter or enhancer elements, and use of vectors from
non-oncogenic retroviruses will hopefully make them safer
for clinical use [43].
Lentivirus
Lentivirus vectors are derived from retroviral vectors but
have the advantage of infecting non-dividing cells. The
most commonly studied lentiviral vectors are derived from
either human immunodeﬁciency virus (HIV) or feline
immunodeﬁciency virus (FIV), although equine anemia
infectious virus and visna virus have also been examined
[38]. The primary concern with HIV vectors is safety. In
contrast, FIV is non-pathogenic in humans and does not
cause serologic conversion [46]. Using an FIV vector,
TNF-a was transduced into primary human FLS with high
efﬁciency. When injected into knees of SCID mice, these
cells induced cell proliferation and caused bone and joint
destruction [47]. A replication-defective HIV vector
encoding endostatin was injected into joints of TNF-a
transgenic mice and was shown to decrease synovial blood
vessel density and decrease the overall arthritis index [48].
Similarly, intra-articular expression of angiostatin inhibited
the progression of CIA in mice [49]. A study examining a
VSV-G pseudo-typed HIV vector, which has increased host
range and stability, demonstrated that a transgene could be
efﬁciently delivered to the synovium of rat knee joints,
with transgene expression lasting up to 6 weeks in immu-
nocompromised animals [50].
AAV
One of the most promising gene transfer vectors is AAV,
which is a small, non-enveloped single-stranded DNA virus
with broad tissue tropism. It belongs to the Parvoviridae
family and has a 4.68kb genome. AAV normally requi-
res adenovirus or herpesvirus to produce active infection.
Several serotypes have been identiﬁed in primates, with
AAV2 being the prototype for most gene transfer studies.
Heparan sulfate proteoglycan has been identiﬁed as the
primary attachment receptor for AAV, with ﬁbroblast
growth factor receptor 1 and integrin avb5 acting as co-
receptors [51]. Although little is known about the details of
AAV infection, some of the basic mechanisms have been
described. The virus enters the cell by receptor-mediated
endocytosis. Acidiﬁcation of late endosomes leads to AAV
release into the cytosol, with subsequent translocation of the
virus to a perinuclear region [52–54]. The virus then enters
the nucleus by an unknown mechanism that is independent
of the nuclear pore complex [55]. Following uncoating, the
single-stranded genome is converted to a double strand and
the viral DNA integrates into chromosome 19 (AAVS1
locus) in a site-speciﬁc manner [56, 57].
AAV is an attractive vector for gene transfer studies for
several reasons. It has been shown to deliver transgenes to
a wide variety of tissues, has low immunogenicity, and
mediates long-term gene expression [51]. Recombinant,
replication incompetent AAV vectors have been designed
that lack the Rep genes, which are required for integration,
so long-term expression with these vectors is thought to be
mediated by episomal viral DNA [58]. In addition, AAV
vectors have been designed that are able to package dou-
ble-stranded viral genomes, bypassing a rate-limiting step
of viral transduction (second-strand synthesis) and allow-
ing rapid and highly efﬁcient transduction both in vitro and
in vivo [59].
Several studies have demonstrated the efﬁcacy of AAV
vectors in arthritis models. Primary and recurrent arthritis
were suppressed following a single injection of AAV
encoding IL-1ra into knee joints of rats with LPS-induced
arthritis. Surprisingly, disease-regulated expression of the
transgene was observed [60]. Our laboratory has recently
observed a similar phenomenon in in vitro cultured FLS
infected with AAV in which inﬂammatory cytokines can
increase transgene expression in these cells in a regulatable,
PI3K-dependent manner. Protesosome inhibition has also
been shown to enhance AAV transduction of human
synoviocytes both in vitro and in vivo [61]. AAV encoding
soluble TNF-a receptor type I decreased synovial cell
hyperplasia and cartilage and bone destruction in human
TNF-a transgenic mice injected intra-articularly with the
virus [62]. Intra-articular or peri-articular delivery of AAV
encoding IL-4 in CIA mice was also shown to decrease paw
swelling, protect from cartilage destruction, and delay the
onset of CIA [63, 64]. A vIL-10 transgene delivered by
AAV under control of a tetracycline inducible promoter
decreased the incidence and severity of CIA on a macro-
scopic, radiologic, and histologic level [65]. More recently,
angiostatin, an anti-angiogenic molecule, was demonstrated
to efﬁciently decrease development of CIA in the treated
joint when delivered by AAV [66].
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cystic ﬁbrosis and hemophilia B and preliminary results are
promising [67]. Targeted Genetics Corporation (Seattle,
WA) is currently conducting a phase I clinical trial (13G01;
identiﬁer NCT00126724) to assess the safety of using an
AAV2 vector to deliver a soluble TNF receptor-Fc fusion
gene in RA.
Gene transfer strategies
IL-1b inhibition
Several gene transfer strategies have been aimed at neu-
tralizing the effects of IL-1b. IL-1b communicates with
many different cell types in the joint. Its action on these
cells leads to emigration of blood cells to the synovium,
increased cartilage destruction, and increased production of
other chemokines and pro-inﬂammatory mediators by
macrophages, B cells, and T cells [7]. Neutralization of this
key cytokine has proven beneﬁcial in the treatment of RA.
Several animal models support using gene transfer to block
the effects of this cytokine. Primary and recurrent arthritis
were suppressed following a single injection of AAV
encoding IL-1ra into knee joints of rats with LPS-induced
arthritis [60]. Adenoviral vectors encoding IL-1ra proved
more effective than soluble type I TNF receptor-IgG fusion
protein at reducing cartilage matrix degradation and
decreasing leukocyte inﬁltration into the joint space of
rabbits with antigen-induced arthritis [13]. Rabbit synovial
ﬁbroblasts modiﬁed ex vivo using a retrovirus encoding IL-
1ra demonstrated a chondroprotective and mild anti-
inﬂammatory effect when injected back into the joint after
onset of antigen-induced arthritis [18]. This led to a phase I
clinical trial using a retroviral vector to deliver IL-1ra to
cultured human autologous synovial ﬁbroblasts. The cells
were then injected into RA patient joints. After a scheduled
arthroplasty 1 week later, signiﬁcant expression of the
transgene was seen in the injected joints, and no adverse
events were reported [17].
Intramuscular injection of plasmid DNA encoding
IL-1ra has also been shown to decrease paw swelling and
arthritis incidence in a CIA mouse model. Reduced syno-
vitis and cartilage erosion were also seen [26, 68]. In a rat
model of bacterial cell wall-induced arthritis, rat synovio-
cytes were modiﬁed ex vivo using a retroviral vector to
express IL-1ra. When injected into ankle joints prior to
reactivation of arthritis, a decreased severity of arthritis
and attenuated destruction of cartilage and bone was
observed [69]. In a SCID mouse model, human RA FLS
transduced with retrovirus encoding IL-1ra co-implanted
with normal human cartilage was able prevent progres-
sive cartilage degradation compared to controls [70]. 3T3
mouse ﬁbroblasts transfected with plasmid encoding IL-1ra
were able to prevent the onset of CIA and cartilage
destruction when injected into knee joints of CIA mice
[12]. Similar effects on arthritis were seen in a rabbit model
of antigen-induced arthritis in which a retroviral vector
carrying the IL-1ra gene was used to transduce rabbit
ﬁbroblasts ex vivo, with subsequent injection of the cells
into the knee joint [15]. More recently, the soluble form of
interleukin-1 receptor accessory protein (sIL-1RAcP) was
delivered to CIA mice either using an adenoviral vector or
by injection of plasmid transfected 3T3 cells. In both
instances, a profound prophylactic effect on the develop-
ment of CIA was observed [71].
TNF-a inhibition
TNF-a is another pro-inﬂammatory cytokine that plays a
key role in the pathogenesis of RA. Many of its effects
overlap those of IL-1b listed above. Currently, therapies
aimed at neutralizing this cytokine represent the most
successful treatment strategies for RA. Current regimens
involve receiving injections (etanercept) or infusions (inf-
liximab) every 2 or 8 weeks, respectively. Gene transfer
strategies have the potential to provide longer-term control
and may also be delivered locally rather than systemically,
potentially minimizing treatment side effects. Several
studies in animal models have been performed. After one
injection at onset of CIA, intramuscular electrotransfer of
plasmids encoding soluble TNF receptor I variants led to a
decrease in clinical and histological signs of CIA [24].
Expression lasted up to 5 weeks and was as least as efﬁ-
cient as repeated injections of the recombinant protein
etanercept in controlling the disease. A similar study using
a retroviral vector to deliver the transgene peri-articularly
saw similar results and also observed a decrease in sys-
temic levels of IgG2a antibodies to collagen type II [72].
Electrotransfer of a plasmid encoding a soluble p75 TNF
receptor:Fc fusion protein was also beneﬁcial in a CIA
model and was associated with a decrease in the levels of
IL-1b and IL-12 in the paw [25]. Other studies using elec-
trotransfer or intramuscular injection of a plasmid with a
doxycycline-regulated promoter to control expression of a
dimeric soluble TNF receptor II molecule saw a therapeutic
effect on CIA only when doxycycline was administered
[73, 74]. In TNF-a transgenic mice, intra-articular delivery
of soluble TNF receptor I by adeno-associated virus led to a
decrease in synovial cell hyperplasia and cartilage and bone
destruction [62]. Similarly, AAV5 encoding sTNFRI-Ig
was also able to decrease paw swelling in a rat AIA model
when expression was under control of an inﬂammation
responsive promoter, but interestingly, not if expression
was under control of the CMV promoter [75].
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transfer collagen type II-induced arthritis when injected into
SCID recipients. If these splenocytes were ﬁrst modiﬁed ex
vivo using retroviral vectors to express soluble p75 tumor
necrosis factor receptor, the SCID recipients did not
develop arthritis, bone erosion, or joint inﬂammation
[76, 77]. Delivery of a rat TNF receptor:Fc fusion protein in
a streptococcal cell wall-induced arthritis model by either
plasmid or local or systemic administration of AAV vectors
encoding the molecule led to decreased inﬂammation,
pannus formation, bone and joint destruction, and mRNA
expression of joint pro-inﬂammatory cytokines [21].
Adenoviral delivery of a soluble TNF receptor type I-IgG
fusion protein directly to rabbit knees with antigen-induced
arthritis reduced-cartilage matrix degradation and
decreased leukocyte inﬁltration into the joint space, espe-
cially when administered in conjunction with a soluble IL-1
type I receptor-IgG fusion protein [13]. The above animal
model data has led to the initiation of a phase I clinical trial
using AAV vectors to deliver soluble TNF Receptor:Fc
fusion protein (Targeted Genetics Corporation).
IL-18 inhibition
IL-18 is a pro-inﬂammatory cytokine that is overexpressed
in the synovium of RA patients and correlates with
inﬂammation. Elevated levels of this cytokine are also
observed in serum and synovial ﬂuid. Overexpression of an
IL-18-binding protein using an adenoviral vector was able
to ameliorate arthritis in a CIA model, indicating neutral-
ization of IL-18 may be an effective target in the future
treatment of RA [78].
Immune deviation
Previously, an imbalance between Th1 and Th2 cytokines
was thought to play a role in the pathogenesis of several
inﬂammatory diseases, including RA. Th1 cells secrete
cytokines like IFN-c that promote a pro-inﬂammatory
environment, while Th2 cytokines secrete cytokines like
IL-4, IL-10, and IL-13 that down-regulate Th1 activity. It
was previously felt that overproduction of Th1 cytokines
contributed signiﬁcantly to the pathogenesis of RA. More
recently, a new subset of T cells, termed Th17 cells, have
been identiﬁed [79]. These cells produce, among other
cytokines, IL-17, a pro-inﬂammatory cytokine previously
implicated in the pathogenesis of CIA [80]. Dysregulation
of Th17 cells and IL-17 overproduction has been impli-
cated in the pathogenesis of inﬂammatory diseases and the
development of severe autoimmunity. In fact, the patho-
genesis of RA may be more directly related to an
imbalance between Th17 cells and Foxp3-positive regula-
tory T cells than an imbalance between Th1 and Th2 cells
[81]. Regardless of the exact mechanism, several strategies
aimed at immune deviation have been successful in animal
models of arthritis and are outlined below.
IL-13 inhibits activated monocytes/macrophages from
secreting a variety of pro-inﬂammatory molecules. A
possible role for this cytokine in the pathogenesis of RA
was observed when adenoviral delivery of IL-13 to RA
synovial tissues explants led to a decrease in IL-1b, TNF-a,
IL-8, MCP-1, NAP-78, PGE2, and MIP-1a when compared
to controls [82]. Subsequent studies demonstrated that
adenoviral delivery of IL-13 directly to ankle joints in a rat
antigen-induced arthritis model signiﬁcantly decreased paw
size, bony destruction, vascularization, inﬂammatory cell
inﬁltration, and inﬂammatory cytokine production [83].
IL-13 overexpression during immune-complex-mediated
arthritis signiﬁcantly decreased chondrocyte death and
MMP mediated cartilage destruction, despite the presence
of enhanced inﬂammation [84].
Using IL-4 to skew the cytokine proﬁle towards Th2, or
perhaps by inhibiting Th17 cell production, has also proven
successful.AdenoviraldeliveryofIL-4toRAsynovialtissue
explants demonstrated decrease IL-1b, TNF-a, IL-8, MCP-
1, and PGE2 in the cultured medium [85]. Intra-articular
deliveryofadenoviralvectorsencodingIL-4toCIAmiceled
to an enhanced onset of inﬂammation but less chondrocyte
deathandcartilageandboneerosion.Proteoglycansynthesis
was enhanced and there was decreased MMP activity [86].
IL-17, IL-12, cathepsin K and osteoprotegrin ligand mRNA
levelswerealsoreduced[86,87].Kimetal.observedsimilar
effects on CIA upon local and systemic administration of
adenoviral vectors encoding IL-4 [88]. AAV-mediated
deliveryofIL-4hasalsoprovebeneﬁcialinCIAmodels[63,
64].ElectrotransferofanIL-4encodingplasmidpriortoCIA
onset decreased synovitis and cartilage destruction, with an
associated decrease in IL-1b in the paw and an increased
TIMP2:MMP2 ratio [29]. Similar results were also seen
usingeithergenegundeliveryorintra-dermaladministration
of plasmid encoding IL-4 [89]. Both retroviral and adeno-
viraldeliveryofIL-4inaratantigen-inducedarthritismodel
had beneﬁcial effects [90–92]. Cell-based therapies that
deliver IL-4 in arthritis models have also been successful.
Injection of ﬁbroblast transfected with plasmid encoding
IL-4decreasedhistologicevidenceofjointinﬂammationand
destructioninaCIAmodel[93,94].Likewise,collagentype
II pulsed antigen presenting cells engineered to secret IL-4
down-regulated CIA [95].
IL-10 is an anti-inﬂammatory cytokine that has dem-
onstrated beneﬁt in several animal models of RA. Either
intramuscular administration via electrotransfer or intra-
dermal injection of plasmid encoding IL-10 had beneﬁcial
effects on CIA [31, 35]. Similarly, systemic administration
Mod Rheumatol (2008) 18:2–14 7
123of a plasmid IL-10/liposome mixture decreased signs of
CIA after a single intra-peritoneal injection [34]. Viral IL-
10 (vIL-10) is homologous to human and mouse IL-10 but
while retaining its immunosuppressive function, it lacks
many of the immunostimulatory properties of IL-10, and
therefore may be a superior treatment option. An adeno-
viral vector encoding vIL-10 was able to decrease CIA
when delivered locally or systemically [14, 96, 97]. Elec-
trotransfer of viral IL-10 decreased histologic evidence of
arthritis in an arthrogen collagen-induced arthritis model
and was associated with decreased TNF-a, IL-1b, and IL-6
transcripts in the joint [30]. A tet-inducible vIL-10 trans-
gene delivered by AAV was able to decrease macroscopic,
radiology, and histologic signs of CIA only when doxy-
cycline was administered [65].
TGF-b is a pleiotropic cytokine with many different
effects on many different cell types and has been suggested
of playing a role in RA. While some of its effects, like
immunosuppression, would appear to be beneﬁcial for RA,
it has also been associated with pro-inﬂammatory activity.
Not surprisingly, data from animal models using gene
transfer support both possibilities, making its true role in
RA difﬁcult to decipher. Splenocytes from CIA mice were
isolated and infected ex vivo with a retroviral vector
encoding TGF-b. These cells were then injected in the
intra-peritoneal cavity 5 days after arthritis onset. Without
TGF-b expression, an exacerbation of arthritis is normally
observed. However, TGF-b expressing splenocytes were
able to inhibit this exacerbation and also resulted in a
decrease in MMP2 activity and a transient reduction in
anti-collagen type II antibodies [98]. In a rat streptococcal
cell wall-induced arthritis model, intramuscular delivery of
plasmid encoding TGF-b showed signiﬁcant decreases in
inﬂammatory cell inﬁltration, pannus formation, bone and
joint destruction, and inﬂammatory cytokine production
[27]. In contrast to the above reports, another study found
that injection of adenovirus encoding TGF-b into the knees
of rabbits with antigen-induced arthritis resulted in signif-
icant pathology in the knee joint and surrounding tissue,
suggesting that TGF-b therapy may not be suitable for
treating arthritis in some models [99].
CTLA-4Ig fusion protein binds to the co-stimulatory
molecules B7-1 and B7-2 present on antigen-presenting
cells and blocks CD28/B7 interactions, resulting in
decreased T cell activation. It has been shown to ameliorate
several experimental autoimmune diseases, including CIA.
A single intravenous injection of an adenovirus encoding
CTLA-4Ig fusion protein suppressed established CIA as
least as efﬁciently as repeated injections of monoclonal
antibody to CTLA-4. Pathogenic cellular and humoral
responses were also diminished in adenoviral vector treated
group as compared to antibody treated and control groups
[100]. CIA could also be inhibited both histologically and
clinically by intra-articular administration of a low dose of
adenovirus encoding CTLA-4Ig fusion protein [101].
Promoting apoptosis
One of the key features of RA is the increased cellularity of
the synovial lining leading to pannus formation, which has
been shown to contribute to cartilage invasiveness and bone
destruction. Promoting synovial apoptosis has been sug-
gested as a treatment strategy for RA. In a rabbit model of
arthritis, intra-articular adenoviral delivery of TNF-related
apoptosis-inducing ligand (TRAIL) was able to increase
apoptosis in the synovial cell lining, decrease inﬂammatory
cell inﬁltration, and promote new matrix deposition [102].
Mice injected with collagen type II-pulsed antigen present-
ing cells engineered to express TRAIL under control of a
doxycycline inducible promoter decreased the incidence of
CIA and inﬁltration of T cells in the joint in the presence of
doxycycline. In situ TUNEL staining demonstrated TRAIL-
induced apoptosis of activated T cells in the spleen [103].
Modulation of TRAIL receptor expression on RA synovio-
cytes has also been suggested as a gene therapy strategy for
the treatment of RA [104].
Injection of adenovirus-expressing Fas ligand (FasL)
into joints of CIA mice induced apoptosis and ameliorated
CIA. IFN-c production by collagen-speciﬁc T cells was
also reduced [105]. Ex vivo modiﬁed T cells engineered to
express FasL were injected into human RA synovial tissue
that had been implanted in SCID mice. Analysis of the
tissue following treatment demonstrated that synoviocytes
and mononuclear cells present in the tissue had been
eliminated by apoptosis through a Fas/FasL interaction
[106]. Similar results were observed when adenovirus
encoding FasL was injected directly into the implanted
tissue [107]. Dendritic cells modiﬁed by adenoviral vectors
to express FasL were able to suppress CIA when system-
ically injected and also demonstrated decreased IFN-c
production from spleen-derived lymphocytes and
decreased T-cell proliferation in response to collagen
stimulation [108]. Fas-associated death domain protein
(FADD) also plays a key role in Fas-mediated apoptosis of
synovial cells. It was found that adenoviral vectors
expressing FADD could induce apoptosis in synoviocytes
both in vitro and in vivo, suggesting that this strategy may
be effective in the treatment of RA [109].
Anti-angiogenesis
Increased cellularity of the synovial lining is also associated
with neo-vascularization in the local environment of the
joint. This angiogenesis is necessary for the development
8 Mod Rheumatol (2008) 18:2–14
123and maintenance of the pannus and also provides nutrients
required for the survival and proliferation of inﬁltrating
inﬂammatory cells [110, 111]. A peptide targeted to the
integrins present in the inﬂamed synovium and associated
with angiogenesis was fused to an anti-apoptotic peptide.
Systemic administration of this fusion peptide in a CIA
model resulted in decreased clinical arthritis and increased
apoptosis of synovial blood vessels [112]. 3T3 ﬁbroblasts
modiﬁed with retroviral vectors to express angiostatin were
able to decrease pannus formation and cartilage erosion
when injected into knee joints of mice with CIA. Arthritis-
associated angiogenesis was also inhibited [113]. AAV and
HIV vector-mediated delivery of angiostatin to CIA knee
joints were similarly beneﬁcial [49, 66]. The potent anti-
angiogenic factor endostatin was able to decrease arthritis
and reduce blood vessel density in a human TNF-transgenic
mouse model of arthritis when delivered to knee joints
using a lentiviral vector [48]. Tie2 has also been demon-
strated to play a role in angiogenesis in arthritis. Adenoviral
delivery of a soluble receptor for Tie2 resulted in a
decreased incidence and severity of CIA, inhibition of
angiogenesis, and was associated with decreased bone
destruction that appeared to result from a decrease in
RANKL [114]. VEGF is another angiogenic factor that
promotes synovitis and bone destruction in arthritis. When
soluble VEGF receptor I was administered via adenoviral
vectors to CIA mice, disease activity was suppressed sig-
niﬁcantly [115]. Thrombospondins (TSP1 and 2) have also
been shown to inhibit angiogenesis and also decrease pro-
inﬂammatory cytokine production in animal models of
arthritis [116, 117]. In addition, adenoviral gene transfer of
a urokinase plasminogen inhibitor was also able to inhibit
angiogenesis in a CIA model [118].
Targeting matrix degradation enzymes
Matrix metalloproteinases (MMPs) degrade extracellular
matrix components and have been demonstrated to con-
tribute to cartilage degradation in RA. Ribozymes and an
antisense construct targeting the destruction of MMP-1
delivered to RA synovial ﬁbroblasts via retroviral vectors
decreased MMP-1 production and reduced the invasiveness
of RA synovial ﬁbroblasts in a SCID mouse model of RA,
suggesting that this may be an effective approach to
inhibiting cartilage destruction in RA [119, 120]. Another
strategy that has proven successful is to increase the ratio
of tissue inhibitors of matrix metalloproteinases (TIMPs) to
MMPs. In a rat antigen-induced arthritis model, intra-
muscular injection of naked DNA encoding TIMP-4
completely abolished the development of the disease [32].
Likewise, adenoviral delivery of TIMP-1 and TIMP-3 to
RA synovial ﬁbroblasts signiﬁcantly decreased their
invasiveness both in vitro and in an in vivo SCID mouse
model of RA. These molecules were found to act by both
decreasing MMP production and reducing cell proliferation
[121].
Targeting NFjB
The transcription factor NFjB plays a signiﬁcant role in
the activation of many cytokines that contribute to the
pathogenesis of RA. Inhibition of this factor could lead to
therapeutic beneﬁt in RA. Injection of decoy oligodeoxy-
nucleotides with high afﬁnity for NFkB into ankle joints of
CIA rats signiﬁcantly decreased joint swelling and joint
destruction. The levels of the pro-inﬂammatory cytokines
TNF-a and IL-1b were also decreased in the treated joints
[122]. Another group found that inhibiting NFjBi nR A
synovial ﬁbroblasts using an adenovirus to deliver a
dominant negative inhibitor of NFjB led to an increase in
apoptosis upon stimulation with TNF-a. These cells are
normally resistant to apoptosis when stimulated with TNF-
a, suggesting that this strategy may be beneﬁcial in the
treatment of RA [123]. In adjuvant arthritis in rats, a
dominant negative IkB kinase b (IKKb) was used to inhibit
the NFjB pathway. Delivering the molecule intra-articu-
larly using an AAV5 vector resulted in signiﬁcantly
reduced paw swelling and decreased levels of IL-6 and
TNF-a. Bone and cartilage destruction, as well as MMP-3
and TIMP-1 levels were unaffected. The same vector was
also able to efﬁciently transduce ex vivo-cultured biopsies
from joints of human RA patients. TNF-a-induced IL-6
production was signiﬁcantly decreased in the ex vivo cul-
tures receiving the vector encoding IKKb [124].
Other strategies
Other molecules that have been demonstrated to play a role
in arthritis using gene transfer in various in vitro or animal
models are Csk, cathepsin L, ﬁbronectin, galectin-1,
p16
INK4A, p21
Cip1, SOCS3, soluble CR1, superoxide
dismutase and catalase, Ras, and prothymosin a [28, 33,
125–136]. Vectors and genes used to successfully treat
animal models of arthritis are summarized in Table 1.
Safety concerns
As with most investigative therapies, one of the most
important concerns with regards to gene transfer technol-
ogies is the issue of safety. While the FDA has outlined
speciﬁc strict standards for clinical trial protocols for gene
transfer studies, there have been several instances where
Mod Rheumatol (2008) 18:2–14 9
123the therapy has resulted in serious adverse events in
patients enrolled in the studies. The most widely known is
probably the September 1999 death of Jesse Gelsinger,
who had a fatal systemic inﬂammatory response to aden-
oviral vector gene transfer [137]. Retroviral vectors have
also resulted in insertional mutagenesis leading to a sec-
ondary malignancy [44]. Lentiviral vectors may have this
potential as well as sharing a similar mechanism, although
this has never been demonstrated in clinical studies. More
recently, in July of 2007, Jolee Mohr, a patient enrolled in
Targeted Genetics’ clinical trial for rheumatoid arthritis
using AAV vectors, died several weeks following her
second injection of the experimental treatment. The trial is
currently suspended, and although the investigation into
her death is still ongoing, initial results suggest she died of
a systemic fungal infection that may be unrelated to the
injected virus. This case and the ﬁnal results of the
investigation are likely to have a large impact on the future
of gene therapy trials in the United States, as AAV has
been heralded as one of the most promising vectors in the
ﬁeld, precisely because it has, until now, failed to reveal
signiﬁcant safety concerns in previous studies.
Future of gene therapy for arthritis
Much progress has been made in the past several years in
the use of gene therapy for the treatment of arthritis.
However, there are many obstacles that must be overcome
in order for it to become a viable treatment option. Future
studies will need to address improving targeted delivery of
vectors, regulating transgene expression, obtaining long-
term transgene expression, and improving the safety and
efﬁcacy of the vectors already in use before gene therapy
becomes a viable clinical therapy for arthritis.
Even in light of the recent setback in clinical trials uti-
lizing AAV vectors, the authors believe that the future of
gene transfer for arthritis will rely heavily upon this vector.
Once the safety issues have been clariﬁed, these trials can
hopefully move forward. Presently, AAV would seem to be
the viral vector that has the best proﬁle in terms of safety,
efﬁcacy, and level and length of transgene expression.
Alternatively, strategies using siRNA technology or pre-
venting the dysregulation of Th17 cells would appear to be
emerging as treatment strategies that may one day outper-
form the current standards of care for rheumatoid arthritis.
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